Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells

Wei-Hong Hou, Lisa Rossi, Ying Shan, Jian-Yu Zheng, Richard W Lambrecht, Herbert L Bonkovsky

Abstract

AIM: To investigate effects of iron on oxidative stress, heme oxygenase-1 (HMOX1) and hepatitis C viral (HCV) expression in human hepatoma cells stably expressing HCV proteins.

METHODS: Effects of iron on oxidative stress, HMOX1, and HCV expression were assessed in CON1 cells. Measurements included mRNA by quantitative reverse transcription-polymerase chain reaction, and protein levels by Western blots.

RESULTS: Iron, in the form of ferric nitrilotriacetate, increased oxidative stress and up-regulated HMOX1 gene expression. Iron did not affect mRNA or protein levels of Bach1, a repressor of HMOX1. Silencing the up-regulation of HMOX1 nuclear factor-erythroid 2-related factor 2 (Nrf2) by Nrf2-siRNA decreased FeNTA-mediated up-regulation of HMOX1 mRNA levels. These iron effects were completely blocked by deferoxamine (DFO). Iron also significantly decreased levels of HCV core mRNA and protein by 80%-90%, nonstructural 5A mRNA by 90% and protein by about 50% in the Con1 full length HCV replicon cells, whereas DFO increased them.

CONCLUSION: Excess iron up-regulates HMOX1 and down-regulates HCV gene expression in hepatoma cells. This probably mitigates liver injury caused by combined iron overload and HCV infection.

Key words: Deferoxamine; Core protein of hepatitis C virus; Hepatitis C; Iron; Heme oxygenase-1; Nuclear factor-erythroid 2-related factor 2; Bach1; Oxidative stress; Nonstructural 5A protein of hepatitis C virus

INTRODUCTION

Iron overload is known to be toxic to many organs, particularly to the liver. The liver is the major site of storage of excess iron. The most common form of iron overload is that related to classic hereditary hemochromatosis, in which, due to mutations in the HFE gene, there is excessive uptake of iron into enterocytes[1-3]. In hemochromatosis, decreased hepatic production and secretion of hepcidin leads to increased ferroportin expression at the plasma membranes,
especially of enterocytes and macrophages. Ferroportin is the only known physiologic iron exporter from cells and its uncontrolled over expression leads to excess uptake of iron from the enterocytes into the portal blood and to increased release of iron from macrophages and other cells of the reticulo-endothelial system, including the Kupffer cells of the liver\[34-36\]. The excess iron in the portal blood and/or released by Kupffer cells within the liver is taken up by hepatocytes where it is stored, chiefly in the form of holo-ferritin. Iron in ferritin is relatively non-reactive and non-toxic. However, release of tissue ferritin from damaged or dying cells leads to activation of hepatic stellate cells and a cascade of pro-inflammatory and pro-fibrogenic events. This may eventuate in the development of hepatic fibrosis, cirrhosis, and hepatocellular carcinoma, as well as all of the usual complications of advanced chronic liver disease\[1-3\].

In recent years, it has become increasingly clear that only modest amounts of iron in the liver may play a role as a co-morbid factor in the development and progression of non-hemochromatotic liver diseases\[7-9\]. The link between iron and non-hemochromatotic liver diseases is particularly strong for steatohepatitis, both non-alcoholic and alcoholic\[10,14,18\] and viral hepatitis B and C\[16-18\].

Porphyria cutanea tarda, the most common form of porphyria, is known to be triggered or exacerbated by iron and is often associated with HFE gene mutations, chronic hepatitis C, and alcohol use\[19-21\]. The treatment of choice for porphyria cutanea tarda involves removal of iron, which leads to remission of the biochemical and clinical features of the disease. Blumberg and colleagues were among the first to stress the importance of iron status in influencing outcomes and progression of acute hepatitis B infection\[22,23\]. In the case of hepatitis C infection, a number of investigators from throughout the world have noted high prevalences (35%-50%) of elevations of serum ferritin and high, albeit somewhat lower, frequencies of elevations of serum transferrin saturation in patients with chronic hepatitis C\[20,24-26\]. Despite this, the occurrence of heavy iron overload in chronic hepatitis C is infrequent and is chiefly related to advanced liver disease. Increases in serum measures of iron and stainable iron in the liver have been directly correlated with more severe chronic hepatitis C and with lower likelihoods of response to currently available antiviral therapy, especially type 1 interferons\[24,27-28\]. In addition, it has been shown repeatedly that reduction of body iron by therapeutic phlebotomy improves the responsiveness of chronic hepatitis C infection to interferon therapy\[29\].

Heme oxygenase-1 (HMOX1) has emerged as a key cytoprotective gene and enzyme in numerous experimental and clinical contexts (For reviews, see\[30-32\]). The HMOX1 gene is under complex regulation and can be up-regulated markedly by heme, the physiologic substrate for the HMOX1 protein, by iron and other transition metallic ions, and by oxidative and heat stress and other stressful perturbations. Regulation of HMOX1 gene expression is related in part to alterations in levels of several transcription factors, including Bach1, and nuclear factor-erythroid 2-related factor 2 (Nrf2). Normally, Bach1 in nuclei represses HMOX1 gene expression, whereas Nrf2, in concert with small Maf proteins, up-regulates its expression\[34-36\].

The study of hepatitis C viral (HCV) infection has been difficult because of the lack of a readily available, inexpensive animal model of acute or chronic hepatitis C infection. The recent development of human hepatoma cell lines, which stably express HCV proteins, and support the replication of HCV RNA or the formation of complete infectious virions of HCV\[37,38\] has facilitated studies on pathogenesis and the role of potential co-morbid factors, such as iron. We used such lines to investigate the effects of iron on oxidative stress, HMOX1 and HCV expression. Here we report that excess iron results in further increased oxidative stress and up-regulation of HMOX1 via Nrf2, and down-regulation of HCV protein expression in human hepatoma cells in culture (Huh-7) expressing HCV RNA and proteins. These effects are reversed by deferoxamine (DFO), the selective and potent iron chelator.

**MATERIALS AND METHODS**

*Reagents and materials*

Mouse anti-HCV nonstructural 5A (NS5A) protein was purchased from Virogen (Plantation, FL). Goat anti-human Bach1, goat anti-human GAPDH polyclonal antibodies, goat anti-mouse IgG, and donkey anti-goat IgG were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). ECL-Plus was purchased from Amersham Biosciences Corp (Piscataway, NJ). Dimethyl sulfoxide was purchased from FisherBiotech (Fair Lawn, NJ). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), zeocin, geneticin, trypsin and TRizol were from Invitrogen Inc. (Carlsbad, CA). FeCl3, Na2NTA, H2O2, 2,7’-dichlorofluorescein diacetate (DCF-DA) and its oxidation-insensitive analog 2,7’-dichlorofluorescein diacetate (DCF-DA) were purchased from Sigma-Aldrich (Allentown, PA). DFO mesylate was from Novartis (Cambridge, MA).

*Cell cultures*

The human hepatoma cell line, Huh-7, was purchased from the Japan Health Research Resources Bank (Osaka, Japan). 9-13 and CNS3 cell lines derived from Huh-7 cells, which stably express HCV proteins were gifts from Dr. R Bartenschlager (University of Heidelberg, Heidelberg, Germany). Human hepatoma Huh-7 cells were maintained in DMEM supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% (v/v) FBS. 9-13 and CNS3 replicon cells were cultured with additional antibiotics (1 mg/mL geneticin or 10 µg/mL zeocin), respectively. 9-13 replicon cells stably express HCV nonstructural proteins (NS3-5B), and CNS3 cells stably express subgenomic proteins from core to nonstructural protein 3 (core-NS3). The Con1 subgenomic genotype 1b HCV replicon cell line was
from Apath LLC (St, Louis, MO). The Con1 cell line is a
Huh-7.5 cell population containing the full-length HCV
genotype 1b replicon. The Con1 cells were maintained in
DMEM supplemented with 10% (v/v) FBS and 0.1
mmol/L nonessential amino acids, 100 U/mL penicillin, 100 µg/mL streptomycin, and selection antibiotic 750
µg/mL genetin. Cells were maintained in a humidified
atmosphere of 95% room air and 5% CO₂ at 37°C.

siRNA transfection
A smart pool of siRNAs targeting four positions of the
human Nrf2 mRNA, was purchased from Dharmacon
(Lafayette, CO). Transfections of Nrf2-siRNA were
performed with Lipofectamine 2000 from Invitrogen
(Carlsbad, CA) as described previously. Cells were
transfected for 48 h with 20-100 nmol/L Nrf2-siRNA, or an irrelevant control, and subsequently were
exposed for 4 h to indicated concentrations of ferric
nitritolriacetate (FeNTA). Cells were harvested and total
RNA and proteins were extracted for measurements
of mRNA or protein levels by quantitative RT-PCR or
Western blots.

Quantitative RT-PCR
Total RNA from treated cells was extracted and cDNA
was synthesized and real time quantitative RT-PCR was
performed using a MyiQ™ Single Color Real-Time PCR
Detection System (BIO-RAD) and iQ™ SYBR Green
Supermix Real-Time PCR kit (BIO-RAD, Hercules, CA)
as described previously. Sequence-specific primers
used for HMOX1, HCV core, NS5A and GAPDH were
synthesized. We included samples without template and
without reverse transcriptase as negative controls,
which were expected to produce negligible signals (Ct
values > 35). Standard curves of HMOX1, HCV core,
NS5A and GAPDH were constructed with results of
parallel PCR reactions performed on serial dilutions of a
standard DNA (from one of the controls). Fold-change
values were calculated by comparative Ct analysis after
normalizing for the quantity of GAPDH in the same
samples.

Western blotting
Protein preparations and Western blots were performed
as described previously. In brief, total proteins
(30-50 µg) were separated on 4%-15% gradient SDS-
PAGE gels (Bio-Rad). After electrophoretic transfer onto
immunoblot PVDF membrane (Bio-Rad), membranes
were blocked for 1 h in PBS containing 5% nonfat dry
milk and 0.1% Tween-20, and then incubated overnight
with primary antibody at 4°C. The dilutions of the
primary antibodies were as follows: 1:500 for anti-NS5A,
1:1000 for anti-Bach1, 1:2000 for anti-HCV core and
anti-GAPDH antibodies. The membranes were then
incubated for 1 h with horseradish peroxidase-conjugated
secondary antibodies (dilution 1:10000). Finally, the
bound antibodies were visualized with the ECL-Plus
chemiluminescence system according to the manufacturer's
protocol (Amersham, Piscataway, NJ). A Kodak 1DV3.6
computer-based imaging system (Eastman-Kodak,
Rochester, NY) was used to measure the relative optical
density of each specific band obtained after western
blotting. Data are expressed as percentages of the controls
(corresponding to the value obtained with the vehicle-
treated cells), which were assigned values of one.

Cellular reactive oxygen species (ROS) production
assay
Levels of cellular oxidative stress were measured using
dCF assay. Briefly, cells were seeded into 24-well plates.
The following day, the media were removed, and the
cells were washed with PBS (PBS supplemented with
1 mmol/L CaCl₂ and 0.5 mmol/L MgCl₂), and then
incubated with 100 µmol/L 2',7'-dichlorodihydrofluores
cin (H₂DCF-DA) or 2',7'-dichlorofluorescein diacetate
(DCF-DA) in DMEM without phenol red for 30 min
at 37°C. The cells were washed twice with PBS, and then treated with selected concentrations of
FeNTA for 1 h. Intracellular ROS levels were measured
as an increase in fluorescence of the oxidized product of
DCF-DA on a Synergy HT Multi-Detection Microplate
Reader (BioTek, Winooski, VT) at the excitation and
emission wavelengths of 488 and 525 nm, respectively.
The oxidation-sensitive analog of H₂DCF-DA served
as a control to correct for possible changes in cellular
uptake, ester cleavage, and efflux. It showed no changes
in fluorescence in these studies.

Statistical analysis
Experiments were repeated at least three times with similar
results. Except for Western blots, all experiments
included at least triplicate samples for each treatment
group. Representative results from single experiments
are presented. Statistical analyses were performed with
JMP 6.0.3 software (SAS Institute, Cary, NC). Initial
interpretation of data showed that they were normally
distributed. Therefore, appropriate parametric statistical
procedures were used: Student’s t-test for comparisons
of two means and analysis-of-variance (F statistics)
for comparisons of more than two, with pair-wise
comparisons by the Kruskal-Wallis test. Values of P < 0.05
were considered significant.

RESULTS
Iron up-regulates HMOX1 mRNA levels in Huh-7 and cell
lines expressing HCV proteins
As shown in Figure 1, HMOX1 gene expression was
significantly increased in CNS3 cells, which express
HCV core to NS3, even without exposure to iron or
hydrogen peroxide, compared to 9-13 cell lines, which
express NS3 to NS5B, or parental Huh-7 cells. Iron, in
the form of FeNTA and hydrogen peroxide (another
known oxidative stressor), further up-regulated the
HMOX1 gene expression in CNS3 cells. Increase of
HMOX1 gene expression by iron in Huh-7 (6.7 fold)
and 9-13 cells (5.2 fold) was greater than in CNS3 cells
(1.9 fold).
Effects of Iron on Nrf2 and Bach1 protein levels in Huh-7 and cell lines expressing HCV proteins

Previous studies from our and other laboratories have demonstrated that Bach1 and Nrf2 act as transcriptional factors that regulate HMOX1 gene expression in mammalian cells[34-36],[34,35], and that Huh-7 cells expressing HCV proteins show significant up-regulation of the HMOX1 gene, and reciprocal down-regulation of the Bach1 gene[37]. To determine whether iron affected the Nrf2 or Bach1 gene expression, parental Huh-7 and cell lines (9-13 and CNS3) expressing HCV proteins were treated with FeNTA, and Nrf2 and Bach1 protein levels were measured by Western blots, as described in Materials and Methods. Cells exposed to 50 and 100 µmol/L FeNTA showed significant accumulation of Nrf2 protein (Figure 2A-C), whereas 50 or 100 µmol/L NaNTA did not affect Nrf2 protein levels (data not shown). In contrast, there were no detectable changes of Bach1 protein levels in either Huh-7 cells or cell lines expressing HCV proteins, suggesting that Bach1 is not involved in up-regulation of the HMOX1 gene expression by iron (Figure 3A-C).

Nrf2-siRNA abrogates up-regulation of the HMOX1 gene expression by iron in 9-13 cells

To further establish the role of Nrf2 in up-regulation of the HMOX1 gene expression by iron, we silenced Nrf2 gene expression by Nrf2-siRNA as we did previously in Huh-7 cells[39]. In comparison with control, 20 nmol/L Nrf2-siRNA significantly reduced Nrf2 protein expression, and 100 nmol/L Nrf2-siRNA repressed Nrf2 protein expression by 92% (Figure 4A). We also successfully silenced the Nrf2 gene expression in CNS3 cells (data not shown). HMOX1 mRNA levels were significantly induced by iron in cells without Nrf2-siRNA transfection, and this effect was blocked in cells transfected with 100 nmol/L Nrf2-siRNA, indicating that Nrf2 siRNA plays a key role in up-regulation of the HMOX1 gene expression by iron (Figure 4B).

Increased ROS, induced by iron, in the form of ferric nitroltriacetate, in the cell lines expressing HCV proteins

Oxidative stress is one of the key stressors inducing the HMOX1 gene expression[30,31],[30,31], occurring due to iron-catalyzed formation of reactive oxygen species (ROS)[42]. We observed that the cells exposed to 50 µmol/L FeNTA exhibited significant increases in the fluorescence intensity of H₂DCF-DA (by 1.4 fold in Huh-7, 1.7 fold in 9-13 and 1.6 fold in CNS3 cells), which are similar to the increases produced by hydrogen peroxide (1 mmol/L). 100 µmol/L FeNTA further increased fluorescence intensity by 2.1 fold in 9-13 and 1.9 folds in CNS3 cells (Figure 5A-C), whereas 50 or 100 µmol/L NaNTA did not affect fluorescence intensity (data not shown). The results of the same experiment done with the oxidation-insensitive analogue of the probe (DCF-DA) in CNS3 (Figure 5D), Huh-7 and 9-13 cells (data not shown) indicated no significant

www.wjgnet.com
difference between control cells and cells treated with FeNTA or H₂O₂. Therefore, the increased fluorescence intensity seen with the oxidation sensitive probe H₂DCF-DA (Figure 5A-C) can be directly ascribed to changes in the oxidation of the probe in the cells. We also changed the order of adding the H₂DCF-DA and FeNTA or H₂O₂ and observed the same pattern of results (data not shown).

The iron chelator DFO blocks increased ROS induced by iron in the cell lines expressing HCV proteins

DFO and deferasirox (Exjade) are widely used iron chelators to remove excess iron from the body. They act by binding iron at 1:1 (deferoxamine:iron) and 2:1 (deferasirox:iron) ratios and enhancing its elimination. By removing excess iron, these agents reduce the damage done by iron to various organs and tissues such as the liver. In this study, DFO was used to examine whether the effects of FeNTA were blocked by DFO chelation. In comparison with 100 µmol/L FeNTA alone, 50 µmol/L DFO (deferoxamine:iron 1:2) significantly decreased DCF fluorescence intensity in 9-13 and CNS3 cells (Figure 6A-C). Indeed, ROS induced by iron were completely blocked by DFO in all three cell lines treated with 50 µmol/L FeNTA and increasing concentrations of DFO (50, 100 and 200 µmol/L) (Figure 6A-C). To confirm we were truly measuring changes in H₂DCF-DA oxidation and not changes in its uptake, ester cleavage, or efflux, we repeated experiments shown in Figure 6A-C with the oxidation-insensitive analogue of the probe (DCF-DA). No significant differences between control
Iron decreases HCV protein expression in cell lines expressing HCV proteins

To evaluate the effect of iron in the form of FeNTA on HCV RNA and protein expression, Con1 full length HCV replicon cells were exposed to FeNTA and with or without DFO. Treatment with FeNTA resulted in a 80%-90% reduction in HCV core mRNA and protein levels (Figure 7A and B), and decreased expression of HCV NS5A mRNA by about 90% and protein by about 50% (Figure 7C and D), whereas no significant effects were produced by NaNTA, establishing that the effects are due to iron and not to the nitrilotriacetate anion (data not shown). These down-regulatory effects were abrogated by DFO (200 μM).

DISCUSSION

The major findings of this work are as follows: (1) Iron, in the form of FeNTA, up-regulates HMOX1 gene expression in human Huh-7, and cell lines (9-13 and CNS3) stably expressing HCV proteins (Figure 1); (2) Iron significantly increases Nrf2 protein levels in human hepatoma cells, and silencing the Nrf2 gene with Nrf2-specific siRNA abrogates the up-regulation of HMOX1 by iron (Figures 2 and 4); (3) Iron does not significantly change Bach1 protein levels in human hepatoma cells (Figure 3); (4) Iron increases ROS (Figures 5 and 6) but...
Hou WH et al. Iron, heme oxygenase-1, and hepatitis C in human hepatoma cells

Figure 4  Silencing the Nrf2 gene abrogates up-regulation of the HMOX1 gene by iron. A: Dose-response effect of Nrf2-specific siRNA on Nrf2 protein levels; B: Effect of Nrf2-specific siRNA on FeNTA up-regulated levels of HMOX1 mRNA. P < 0.05 vs control. 9-13 cells were transfected with selected concentrations of Nrf2-siRNA (0, 20, 50, 100, 150 nmol/L). After 48 h of transfection, cells were treated with different concentrations of FeNTA (0, 50, 100 µmol/L) for 6 h, after which cells were harvested and total RNA was isolated. The HMOX1 mRNA levels were measured by quantitative RT-PCR as described in Materials and Methods.

HMOX1 is a heat shock protein (also known as HSP 32), which can be induced to high levels, not only by heat shock, but also by a large number of physiological or pathological stressors. Nrf2 is a basic leucine zipper transcriptional activator[35,48]. It protects cells against oxidative stress through antioxidant response element (ARE)-directed induction of several phase 2 detoxifying and antioxidant enzymes, including HMOX1[35,46]. Nrf2-/- mice displayed a dramatically increased mortality associated with liver failure when fed doses of ethanol that were tolerated by wild type mice, establishing a central role of Nrf2 in the natural defense against ethanol-induced liver injury[47]. Cobalt protoporphyrin (CoPP)-mediated induction of HMOX1 involves increased Nrf2 protein stability in human hepatoma Huh-7 cells[35]. In this study, silencing Nrf2 by Nrf2-siRNA markedly abrogated FeNTA-mediated up-regulation of HMOX1 mRNA levels. Therefore Nrf2 plays a central role in up-regulation of HMOX1 gene expression by FeNTA (Figure 4B).

Expression of HMOX1 was recently reported to be decreased in human livers from patients with chronic hepatitis C[34,55] including some with only mild fibrosis. The reasons for this are not known currently. It is known that levels of expression of the HMOX1 gene depend in part upon genetic factors (lengths of GT repeats in the promoter[60,61] and a functional polymorphism (A/T) at position -413 of the promoter[62,63]). Higher expression and/or induction of HMOX1 are probably beneficial to mitigate liver cell injury in HCV infection, as well as in other liver diseases. This may be a therapeutic goal, achieved by treatment with heme or CoPP or with silymarin[62] or other herbal products or compounds that combine anti-oxidant, iron-chelating and HMOX1-inducing effects.

Recently, we showed that HCV expression in CNS3 cells increases the levels of HMOX1 mRNA and protein[64]. This induction is likely in response to oxidative stress. More recently, we showed that micro RNA-122, which is expressed at a high level in hepatocytes, causes down-regulation of Bach1, which, as already described,
Figure 5 Effects of FeNTA on intracellular ROS in Huh-7, 9-13, and CNS3 cells. A: Fluorescence intensity with the H$_2$DCF-DA probe in Huh-7 cells; B: Fluorescence intensity with the H$_2$DCF-DA probe in 9-13 cells; C: Fluorescence intensity with the H$_2$DCF-DA probe in CNS3 cells; D: Fluorescence intensity with the (control) DCF-DA in CNS3 cells. Cells were preincubated with 100 µmol/L H$_2$DCF-DA or DCF-DA for 30 min, and then exposed to selected concentrations of FeNTA (0, 50, 100 µmol/L) for 1 h. Intracellular ROS production was measured as described in Materials and Methods. Data represent fluorescence intensity measured and expressed as relative fluorescence units per milligram total protein (mean ± SE, n = 3 experiments). *P < 0.05 vs control.

Figure 6 Effects of deferoxamine on intracellular ROS induced by FeNTA in Huh-7, 9-13, and CNS3 cells. A: Fluorescence intensity with the H$_2$DCF-DA probe in Huh-7 cells; B: Fluorescence intensity with the H$_2$DCF-DA probe in 9-13 cells; C: Fluorescence intensity with the H$_2$DCF-DA probe in CNS3 cells; D: Fluorescence intensity with the (control) DCF-DA in CNS3 cells. Cells were loaded with 100 µmol/L H$_2$DCF-DA for 30 min, treated with different concentrations of deferoxamine (50, 100, 200 µmol/L) for 30 min, and then exposed to different concentrations of FeNTA (50, 100 µmol/L) for 1 h. Intracellular ROS production was measured as described in Materials and Methods.
1.2

Hou WH et al. Iron, heme oxygenase-1, and hepatitis C in human hepatoma cells

Figure 7 Effects of FeNTA on HCV core and NSSA mRNA and protein levels. A: Core mRNA levels in Con1 cells treated with FeNTA and with or without deferoxamine; B: Core protein levels in Con1 cells treated with FeNTA and with or without deferoxamine; C: NSSA mRNA levels in Con1 cells treated with FeNTA and with or without deferoxamine; D: NSSA protein levels in Con1 cells treated with FeNTA and with or without deferoxamine. Data are presented as mean ± SE from triplicate samples, all normalized to GAPDH in the same samples. *P < 0.05 vs control. The Con1 full length HCV replicon cells were treated with indicated concentrations of FeNTA and with or without deferoxamine. After 24 h, cells were harvested and total RNA and proteins were extracted. Levels of mRNA were measured by quantitative RT-PCR, and protein levels were determined by Western blots as described in Materials and Methods. Values for cells without any treatment were set equal to 1.

Regardless of these results in cell culture models, the preponderance of clinical evidence[10-15,24-29] supports the view that iron acts as a co-morbid or synergistic factor in chronic hepatitis C infection. Because both iron and HCV infection increase oxidative stress within hepatocytes, one attractive mechanistic explanation for the additive or synergistic affects of these two perturbations is that they act, at least in part, by increasing oxidative stress in the form of highly reactive oxygen species. These considerations provide additional rationale for the notion that reduction of iron and antioxidant therapy[69-72] may be of benefit in the management of difficult to cure chronic hepatitis C[10-15,24-29,66-68]. Iron reduction has usually been achieved with therapeutic phlebotomies. However, deferasirox (Exjade) recently has been approved in the USA and other countries as oral chelation therapy for iron overload states. Thus, studies of deferasirox for therapy of chronic hepatitis C are timely and important[69], especially because the therapy of chronic hepatitis C currently is fraught with side effects, difficulties of adherence and rates of response that are not better than about 50%[69-72].

In conclusion, iron can cause or exacerbate liver damage, including viral hepatitis. In the work reported in this paper we assessed effects of iron and iron chelators on liver cells, some of which also expressed genes and proteins of the HCV. Iron increased oxidative stress...
and led to up-regulation of the HMOX1 gene, a key cytoprotective gene. A mechanism for this action was to increase expression of the positive transcription factor Nrf-2. In contrast, iron did not affect expression of Bach1. Iron decreased expression of HCV genes and proteins. All the effects of iron were abrogated by DFO. The induction of HMOX1 helps to protect liver cells from the damaging effects of the HCV.

ACKNOWLEDGMENTS

We thank Ralf Bartenschlager (University of Heidelberg, Germany) for kindly supplying the HCV replicon cells used in this paper and Melanie McDermid for help in preparing the manuscript.

COMMENTS

Background

Iron overload is known to be toxic to many organs. The most common form of iron overload is hereditary hemochromatosis. In this disease, iron overload results in damage to many organs including the heart, pancreas and liver. In fact, the main site of iron deposition is in the liver. Recently it has been learned that iron plays a role in non-hemochromatotic liver disease. By insight into the mechanisms of how iron leads to this damage, novel ways to improve outcomes and success in treating these liver diseases may be achieved. One such liver disease is chronic hepatitis C.

Research frontiers

Currently chronic hepatitis C affects more than 170 million people worldwide. Standard therapy consists of a combination of pegylated alpha interferon and ribavirin. This is a difficult treatment regimen consisting of almost 1 year of therapy in many cases. Unfortunately, there is only a 50% success rate for treatment overall. There is much ongoing research seeking to improve this success rate. Until recently there were no tissue culture models for investigating hepatitis C, but cell lines have been developed which support hepatitis C viral (HCV) replication. These models allow for a unique and new way to investigate HCV replication and pathogenicity.

Innovations and breakthroughs

This article examines the role of iron in inducing heme-oxygenase 1 (HMOX1) in a tissue culture model of hepatitis C. HMOX1 is a heat shock protein that is induced by physiologic and pathologic stressors. Oxidative stress is one such stressor. The authors have shown that HMOX1 is up regulated in cell lines that express HCV proteins. The addition of iron in the form of ferric nitritolactate (FeNTA) to these cell lines further upregulates HMOX-1 gene expression. This up regulation is independent of Bach1, a protein which functions to suppress HMOX-1 expression. Conversely the expression of HCV proteins was down-regulated when HMOX1 was induced. The induction of HMOX1 likely helps to protect liver cells from the damaging effects of the HCV. The iron chelators defereroxamine (Desferal) and deferasirox (Exjade) blocked the effects of FeNTA in generating reactive oxidative stress as measured by fluorescence.

Applications

Clinical evidence supports the view that iron acts as a co-morbid factor in chronic hepatitis C infection. This may be a result of the increased oxidative stress caused by both iron and HCV infection. Therefore the use of anti-oxidant therapy and iron chelators could be of benefit in the treatment of chronic HCV infection. Recently, deferasirox (Exjade) has been approved in the USA and other countries to treat iron overload states. Studies using deferasirox as an adjunct to the treatment of hepatitis C may be an aid to advance the therapy for chronic hepatitis C.

Peer review

The manuscript is a very well written and well-designed study. In this study authors have shown the critical role of iron on HCV expression and potential use of anti-chelating agents to treat the HCV patients. The study is novel.

REFERENCES

1. Franchini M, Veneri D. Hereditary hemochromatosis. Hematology 2005; 10: 145-149
2. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127: S79-S86
3. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathophysiology of hereditary hemochromatosis. Semin Liver Dis 2005; 25: 411-419
4. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-19912
5. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Møyruhn J, Pav BH, Drejer A, Barut Z, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LJ. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781
6. McKie AT, Marciani P, Rolls A, Brennan K, Weir K, Barrow D, Miret S, Bonford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299-309
7. Bertino G, Ardiri AM, Boemi PM, Ierna D, Scuito M, Cilio D, Pulvirenti D, Neri S. [Hepatic iron, iron depletion and response to therapy with peg-Interferon and Ribavirin in chronic hepatitis C. Pilot study] Clin Ter 2007; 158: 391-395
8. Britton RS, Ramm GA, Olynyk J, Singh R, O'Neill R, Bacon BR. Pathophysiology of iron toxicity. Adv Exp Med Biol 1994; 356: 239-253
9. Halliday JW, Ramm GA, Moss D, Powell LW. A new look at ferritin metabolism. Adv Exp Med Biol 1994; 356: 149-156
10. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996; 16: 65-82
11. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-768
12. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin Liver Dis 2000; 4: 409-429, vi-vii
13. Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, Mehta S, Koff RS, Liu Q, Hsieh CC. Iron and HFE or TIR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002; 37: 848-854
14. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30: 137-144
15. Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005; 25: 461-472
16. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997; 41: 115-120
17. Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol 2004; 99: 286-291
18. Fujita N, Sugimoto R, Takeo M, Urawa N, Mitufu R, Tanaka H, Kobayashi Y, Iwasa M, Watanabe S, Adachi Y, Kaito M. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 2007; 13: 97-104
19. Bonkovsky H, Lambrecht R. Hemochromatosis, iron overload, and porphyria cutanea tarda. In: Barton JC ECQ, Bofakovsky HL (eds), Clin Liver Dis 4: 97-104
20. Teubner A, Richter M, Schuppan D, Köstler E, Stölzel U. [Hepatitis C, hemochromatosis and porphyria cutanea tarda] Dtsch Med Wochenschr 2006; 131: 691-695
21. Bonkovsky HL, Pohl-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercuro MG, Lambrecht RW. Porphyria cutanea tarda, hepatitis C,
and HFE gene mutations in North America. Hepatology 1998; 27: 1661-1669

22 Felton C, Lustbader ED, Merten C, Blumberg BS. Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci USA 1997; 94: 24325-24331

23 Lustbader ED, Hann HW, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220: 423-425

24 Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana R, Di Bisceglie AM, Ghany MG, Morishima C. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006; 131: 1440-1451

25 Di Bisceglie AM, Afoxitis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-2113

26 Arber N, Konikoff FM, Moshkovitz M, Baratz M, Hallak A, Santo M, Halpern Z, Weiss H, Gilat T. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994; 39: 2656-2659

27 Van Thiel DH, Friedlander L, Faginouli S, Wright HJ, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-415

28 Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schuff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-1109

29 Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008; 53: 815-822

30 Bonkovsky HL, Elbirt KK. Heme oxygenase: its regulation and role. In: Cutler RG, Rodriguez H, editors. Oxidative stress and aging. River Edge, NJ: World Scientific, 2002: 699-706

31 Elbirt KK, Bonkovsky HL. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians 1999; 111: 438-447

32 Hill-Kapturczak N, Chang SH, Agarwal A. Heme oxygenase and the kidney. DNA Cell Biol 2002; 21: 307-321

33 Lambrecht RW, Fernandez M, Shan Y, Bonkovsky HL. Heme oxygenase and carbon monoxide in cirrhosis and portal hypertension. Ascites and renal dysfunction in liver disease. 2nd ed. Oxford: Blackwell Science, 2005

34 Igarashi K, Hoshino H, Muto A, Suwabe N, Nishikawa S, Nakauchi H, Yamamoto M. Multivalent DNA binding complex generated by small Maf and Bach1 as a possible biochemical basis for beta-globin locus control region complex. J Biol Chem 1998; 273: 11783-11790

35 Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J 2006; 20: 2567-2653

36 Sun J, Hoshino H, Takaku K, Nakajima O, Muto A, Suzuki H, Tashiro S, Takahashi S, Shibahara S, Alam J, Taketo MM, Yamamoto M, Igarashi K. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 2002; 21: 5216-5224

37 Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartschdegner R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113

38 Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartschdegner R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001; 75: 1252-1264

39 Schmidt R. Cobalt protoporphyrin as a potential therapeutic agent? FASEB J 2007; 21: 2639; author reply 2640

40 Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007; 133: 1166-1174

41 Ghaziani T, Shan Y, Lambrecht RW, Donohue SE, Pietschmann T, Bartschdegner R, Bonkovsky HL. HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol 2006; 45: 5-12

42 Nagasawa T, Hatayama T, Watanabe Y, Tanaka M, Niisato Y, Kitts DD. Free radical-mediated effects on skeletal muscle protein in rats treated with Fe-nitroliatriacetate. Biochem Biophys Res Commun 1997; 231: 37-41

43 Fillebeen C, Rivas-Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW, Koromilas AE, Pantopoulos K. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem 2005; 280: 9034-9047

44 Andrews NC, Erdjument-Bromage H, Davidson MB, Tempst P, Orkin SH. Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature 1993; 362: 722-729

45 Peters LL, Andrews NC, Eicher EM, Davidson MB, Orkin SH, Lux SE. Mouse microcytic anaemia caused by a defect in the gene encoding the globin enhancer-binding protein NF-E2. Nature 1993; 362: 768-770

46 Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of peroxynitrite. Proc Natl Acad Sci USA 2001; 98: 4611-4616

47 Lamlé J, Marhenke S, Börjak L, von Waiselwassert R, Erissson CJ, Geffer S, Manns MP, Yamamoto M, Vogel A. Nuclear factor-erythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 2008; 134: 1159-1168

48 Suzuki T, Tashiro S, Hira S, Sun J, Yamazaki C, Znake Y, Ikeda-Saito M, Yoshida M, Igarashi K. Heme regulates gene expression by triggering Crml-dependent nuclear export of Bach. EMBO J 2004; 23: 2544-2553

49 Igarashi K, Sun J. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid Redox Signal 2006; 8: 107-118

50 Abate A, Zhao H, Wong RJ, Stevenson DK. The role of Bach1 in the induction of heme oxygenase by tin mesoporphyrin. Biochem Biophys Res Commun 2007; 354: 757-763

51 Igarashi K, Sun H. [Oxidative stress protection by heme] Masiu 2002; 51 Suppl: S16-S25

52 Shan Y, Lambrecht RW, Ghaziani T, Donohue SE, Bonkovsky HL. Role of Bach1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAs. J Biol Chem 2004; 279: 51769-51774

53 Hou W, Shan Y, Zheng J, Lambrecht RW, Donohue SE, Bonkovsky HL. Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1. Biochim Biophys Acta 2008; 1779: 195-203

54 Abdalla MY, Britigan BE, Wen F, Icardi M, McCormick ML, LaBrecque DR, Voigt M, Brown KE, Schmidt WN. Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J Infect Dis 2004; 190: 1109-1118

55 Wen F, Brown KE, Britigan BE, Schmidt WN. Hepatitis C core protein inhibits induction of heme oxygenase-1 and sensitizes hepatocytes to cytotoxicity. Cell Biol Toxicol 2008; 24: 175-188

56 Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000; 66: 187-195

57 Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Chang MJ, Wu TC, Chen LC, Ding YA, Pan WH, Jou YS, Chau LY. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum
Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, Aizawa T, Ishizaka N, Nagai R. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002; 22: 1680-1685

Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004; 37: 1097-1104

Ono K, Goto Y, Takagi S, Baba S, Tago N, Nonogi H, Iwai N. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis 2004; 173: 315-319

Ono K, Mannami T, Iwai N. Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. J Hypertens 2003; 21: 1497-1503

Bonifaz V, Shan Y, Lambrecht RW, Donohue SE, Moschenross D, Bonkovsky HL. Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int 2009; 29: 366-373

Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581

Jopling CL, Norman KL, Sarnow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol 2006; 71: 369-376

Fillebeen C, Muckenthaler M, Andriopoulos B, Bisaitillon M, Mounir Z, Hentze MW, Koromilas AE, Pantopoulos K. Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J Hepatol 2007; 47: 12-22

Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-988

Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136: 667-672

Yano M, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Shiono Y, Arao M, Ukai K, Ito H, Watanabe K, Yoshioka K. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002; 97: 133-137

Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J Hematol 2007; 82: 1142-1146

Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965

S- Editor Tian L  L- Editor O’Neill M  E- Editor Zheng XM